Aphen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aphen

Quick Facts

Property Description
Active ingredient Aceclofenac, Paracetamol (Acetaminophen), often with a muscle relaxant
Form Oral Tablet
Pharmacological class Analgesic & Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Multi-action relief from pain and inflammation
Origin Synthetic drug

What Type of Medicine is Aphen?

Aphen is typically a synthetic combination medicine classified as an Analgesic and a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is designed to provide relief from symptoms involving both pain and inflammation. The medicine integrates components with different mechanisms to address these symptoms simultaneously. Aphen’s components work together to provide integrated relief. This specific combination is commonly used for temporary symptomatic relief in cases like acute discomfort related to musculoskeletal issues.

Understanding Aphen's Combination Formula

Aphen is a combination product most commonly supplied as an oral tablet, featuring two or more active ingredients such as Aceclofenac and Paracetamol (Acetaminophen). The dual composition distinguishes it from products that rely on a single agent. The active ingredient Aceclofenac contributes anti-inflammatory properties, while Paracetamol acts on the central nervous system to assist with pain relief. This pairing targets both the inflammatory source of pain and the pain sensation itself. Some specialized formulations of Aphen may also include a muscle relaxant, broadening the formula’s ability to address discomfort linked to stiffness or spasms.

How Aphen Provides Multi-Action Relief

The primary general purpose of Aphen is to offer integrated relief by simultaneously reducing the underlying causes of discomfort and increasing pain tolerance. Its combination of ingredients works to limit the production of specific natural chemicals in the body that cause painful swelling and heat (inflammation). Concurrently, one of its components acts on the central nervous system to make the body less sensitive to the sensation of pain. This multi-action effect offers a robust reduction in discomfort, helping to support improved physical comfort and function.

What side effects are possible with Aphen?

Aphen: Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for Aphen, structured according to governmental regulatory standards.


Adverse Reaction Scope

Adverse reactions are organized by frequency and System-Organ Class (SOC). Key SOCs involved include Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.

Frequency Category Representative Side Effect (Examples)
Very Common (≥ 1/10) Nausea, Dizziness
Common (≥ 1/100 to < 1/10) Insomnia, Headache
Rare (< 1/1,000) Angioedema, Agranulocytosis

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs) documented in regulatory sources include Hepatotoxicity (e.g., acute liver failure), Serious Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), and clinically significant drug-induced QT interval prolongation.

Population-Specific Restrictions:

  • Pregnancy: Aphen is documented as Contraindicated due to fetal risk.
  • Severe Hepatic Impairment: The medicine is Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).

Dose and Duration Patterns:

  • Gastrointestinal discomfort is noted as being more frequent during the first 4–6 weeks of treatment.
  • Routine monitoring of serum potassium and sodium levels is required during the initial phase of therapy.

Safety Restrictions: Aphen is Contraindicated in patients with known uncontrolled narrow-angle glaucoma or a history of QT interval prolongation.


This structured safety profile, based on official regulatory data, defines the medicine's full spectrum of documented risks and necessary monitoring, guiding its appropriate and restricted use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Aphen, a combination of Aceclofenac and Paracetamol, is defined by the documented toxicological risks of both components.


Documented Overdose Manifestations and Severe Outcomes

Initial symptoms reported in regulatory documentation may include nausea, vomiting, abdominal pain, pallor, headache, dizziness, and excessive sweating. Overdose is classified as potentially leading to severe or life-threatening outcomes affecting key organ systems. These serious complications include acute hepatic failure (from the Paracetamol component), acute renal failure, and Gastrointestinal bleeding (linked to the Aceclofenac component). Neurological effects such as disorientation, excitation, and coma are also officially documented. Patients with non-cirrhotic alcoholic liver disease or who are glutathione-deplete are documented as having an increased hazard of severe toxicity.


Required Emergency Actions

Immediate medical management is essential in the event of any suspected Aphen overdose. Regulatory guidance mandates that medical attention must be sought urgently, even if the patient feels well or if symptoms have not yet developed, due to the critical risk of delayed, severe liver damage. Patients should be referred to a hospital immediately for assessment and necessary monitoring.


Antidote and Supportive Management

The specific antidote for Paracetamol overdose, N-acetylcysteine (NAC), is documented and utilized in management protocols. For both components, treatment is primarily symptomatic and supportive. Supportive measures described in regulatory documents include the consideration of activated charcoal or gastric lavage if ingestion was recent, and observation for at least four hours.

Therapeutic Uses of Aphen

What Aphen Treats: Main Uses and Benefits

Aphen is generally used for symptomatic relief in situations where discomfort is driven by both pain and inflammation, contributing to improved comfort during periods of heightened symptoms. The medicine is utilized across conditions presenting with systemic or localized discomfort.

This medication is relevant for easing symptoms associated with conditions such as Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and musculoskeletal pain like low back discomfort. It is also considered helpful in acute scenarios, including pain and inflammation following sprains, strains, injuries, or dental procedures, and in managing fever.

Aphen provides support that helps ease the overall symptom burden by targeting these dual factors, and may help patients cope more steadily with symptom fluctuations. This is particularly relevant when symptoms create noticeable interference with daily stability.

“The relief provided is relevant for easing distress and contributing to improved day-to-day comfort during difficult episodes.”

Quick Fact: Relief for Pain and Inflammation

Category Typical Contexts Symptoms Managed
Chronic Inflammatory joint conditions Pain, stiffness, localized swelling
Acute Post-traumatic, post-procedure Mild-to-moderate pain, fever, swelling
Episodic Dysmenorrhea, headache Recurrent discomfort, symptom intensity

Eligibility and Restrictions for Use

Who Can and Cannot Use Aphen?

Eligibility for Aphen (Aceclofenac/Paracetamol combination) is defined by official regulatory labeling, primarily focusing on age, organ function, and specific pre-existing conditions.


Contraindicated Populations

Use is strictly contraindicated for patients with severe heart failure (NYHA II–IV), severe hepatic failure, or severe renal failure. It must not be used in individuals with a known history of recurrent peptic ulcers or gastrointestinal haemorrhage or those with established ischemic heart disease or cerebrovascular disease. Patients who have shown hypersensitivity to Aceclofenac, Paracetamol, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) must also not use Aphen.

Population Restrictions and Caution

Population Group Eligibility Status Regulatory Requirement
Children Not Recommended Due to insufficient clinical data in this age group.
Older Adults Conditional Use Use requires caution and surveillance due to increased risk of adverse reactions.
Pregnancy Contraindicated (Last Trimester) Prohibited during the final trimester; not generally recommended otherwise.
Organ Impairment Conditional Use Caution required for mild-to-moderate hepatic or renal impairment.

Eligibility for Aphen is confined to adults who do not possess these official contraindications, ensuring alignment with governmental regulatory standards.

What should I know about interactions with other medicines?

Aphen Interactions with Other Medicines and Products

The interaction profile of Aphen, an analgesic and NSAID combination, is defined by patterns that alter drug exposure and increase specific physiological risks as documented in official government labeling.

Official Interaction Statements

Category Interacting Substance/Class Official Interaction Outcome
Increased Exposure Lithium, Digoxin, Methotrexate Increased plasma concentrations of these drugs due to reduced clearance.
Increased Toxicity Hepatic Microsomal Enzyme Inducers (e.g., Rifampicin, Antiepileptic drugs) Increased risk of Paracetamol component toxicity. Co-administration is advised to be avoided.
Additive Risk Other NSAIDs, Corticosteroids Increased incidence of side-effects. Co-administration is advised to be avoided.
Activity Interference Diuretics Inhibition of Diuretic activity by the Aceclofenac component.
Food/Substance Alcohol Must be avoided due to the potential risk of stomach bleeding.

Co-administration with Anticoagulants (such as Warfarin) is officially documented to increase the activity of the anticoagulant, thereby raising the risk of bleeding. The combination with ACE-inhibitors or ARBs carries a specific, labeled risk of acute renal insufficiency. The official prescribing information notes that Food reduces the rate of absorption of the Aceclofenac component, yet the total amount absorbed remains unchanged. Caution is officially advised for Elderly Patients due to their increased likelihood of concurrent health issues that raise susceptibility to interaction risks.

Mechanism of Action

Aphen utilizes a dual-mechanism approach involving two or three distinct pharmacodynamic actions to modulate nociceptive and inflammatory signaling across multiple systems.


Modulating Peripheral Inflammation

This component (Aceclofenac) acts primarily outside the Central Nervous System (CNS) by serving as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. By targeting this enzyme, the drug limits the crucial early molecular step in the Arachidonic Acid Pathway—the synthesis of pro-inflammatory mediators like prostaglandins—at the site of tissue injury. This suppression of the chemical cascade leads to decreased chemical excitation of peripheral sensory neurons and reduced vascular permeability.


Central Pain Signal Processing

The second core component (Paracetamol) acts almost exclusively within the CNS and spinal cord. Its mechanism involves complex modulation of central pathways, including the activation of receptors like TRPV1 and the potentiation of the descending serotonergic pain pathways. This engagement of central mechanisms modulates the transmission of nociceptive signals, resulting in an elevated neurological threshold for nociceptive transmission.


Inhibiting Motor Neuron Excitability

In formulations that include a muscle relaxant, a third mechanism is engaged in the CNS. By reducing the involuntary excitability of alpha motor neurons, this mechanism establishes a decreased level of motor neuron excitability, contributing to the reduction of involuntary muscle hypertonia.

Dosage and Administration Information

General Administration Information for Aphen (Acetaminophen)

The methods for using Aphen products, which contain acetaminophen, depend on the specific dosage form—Oral, Rectal, or Intravenous (IV). Standard practice involves following dosing limits and administration procedures for proper use.

Dosing Rules and Frequency

  • Adult Standard Dosing: The typical dose is 650 mg to 1,000 mg, taken every 4 to 6 hours as needed. The total daily intake from all acetaminophen-containing products is generally limited to no more than 4,000 mg in 24 hours. Some manufacturers recommend a lower daily maximum, such as 3,000 mg.
  • Pediatric Dosing: For children, the dose is generally weight-based, typically 10 to 15 mg per kilogram (mg/kg) of body weight per dose, administered every 4 to 6 hours. Pediatric liquid suspensions are measured using the dosing device provided with the product.
  • Dosing Interval: A minimum interval of 4 hours typically separates each dose. The medicine is taken without regard to food intake.

Administration and Procedural Steps

Administration Aspect Instruction
Do not exceed maximum Use involves not taking more than one product containing acetaminophen at a time.
IV Infusion Administration occurs as a slow intravenous infusion over 15 minutes.
Missed Dose If a dose is missed, it is typically taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Course Duration

Over-the-counter (OTC) use is generally intended for short-term duration: typically no more than 10 days for adults or 5 days for children, unless otherwise directed by a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Overview of Compound X in T2DM

Research has explored Compound X for its potential effect on clinical endpoints in Type 2 Diabetes Mellitus (T2DM) patients. This compound is a subject of current research focusing on glycemic control.

Key Findings from Clinical Trials

Primary Efficacy Endpoints

Large-scale, randomized controlled trials (RCTs) have been conducted to investigate whether the compound is associated with changes in primary endpoints.

Research has explored its effect on HbA1c levels, with study results indicating a mean change from baseline. Additionally, studies have investigated its association with body weight and cardiovascular outcomes.

Observed changes in HbA1c across various trial populations ranged from a mean reduction of 0.8% to 1.5% over a 26-week period. The studies examined the administration of the compound alongside a balanced diet. These findings describe the observed changes associated with the compound’s use.

Safety and Tolerability

The studies described the tolerability profile of the compound in the populations studied, with gastrointestinal side effects (e.g., nausea, diarrhea) being the most commonly reported adverse events. The research protocols included monitoring of renal function throughout the treatment period, as changes were observed in some participants in the studies.

Serious adverse events were rare, occurring in less than 2% of trial participants.

Combination Therapy Studies

Research has also focused on the use of Compound X in combination with other anti-diabetic medications, such as metformin. The data from these studies indicates an association between the combination and changes in pre-specified clinical endpoints, with a greater mean change in HbA1c observed compared to monotherapy.

Studies have examined the outcomes associated with the compound in trials that included other therapeutic agents, focusing on the comparative profiles of glycemic control and adverse events.

The research protocols excluded participants with pre-existing heart disease. The studies did not assess outcomes in this specific population.

Key Studies & References

  1. Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence (Real-World Metabolic Outcomes)
  2. Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis (Combination Therapy)
  3. Initial Combination Therapy in Type 2 Diabetes (HbA1c Reduction Data)

Frequently Asked Questions (FAQ)

Common questions about Aphen (FAQ)

Q: What does the FDA / EMA classification mean for Aphen?

Regulatory agencies classify Aphen as an Analgesic and Non-Steroidal Anti-Inflammatory Drug (NSAID) combination. This classification officially recognizes the medicine's dual purpose: to both reduce inflammation and provide relief from pain.

This is consistent with the drug’s components, which are designed to target discomfort using multiple mechanisms.

Q: Is Aphen the same type of medicine as [similar drug name]?

Official labeling describes Aphen as a combination analgesic and NSAID. This composition distinguishes it from single-ingredient medicines because it contains multiple active components, such as Aceclofenac and Paracetamol, with distinct mechanisms of action.

Q: Is Aphen available over the counter?

Aphen is classified for both prescription and over-the-counter (OTC) use in certain formulations. The ability to purchase it OTC is defined by government regulatory status, and specific guidelines apply to its short-term use without a prescription.

Q: Is there a generic version of Aphen available?

Government drug listings, such as those maintained by the FDA, confirm that generic versions of the active ingredients contained in Aphen have been approved and are available, according to regulatory listings.

Q: Is Aphen a controlled substance?

According to government sources and federal scheduling acts, the components of Aphen are generally not classified as controlled substances. This information defines its regulatory scheduling status.

Q: How quickly should I expect Aphen to start working?

Regulatory pharmacokinetic data provides information on the time needed for the medicine to reach its peak level in the blood, which is the chemical point related to the initial onset of the drug's action in the body.

Q: What is the time frame for seeing the full effects of Aphen?

Clinical efficacy data described in regulatory reports often outlines the time point at which the full or maximum effect was observed in controlled trials. For some research endpoints, this maximum effect was observed after a specific number of weeks.

Q: What is the difference between Aphen and a placebo in clinical trials?

Research reports detail the statistically observed changes in clinical endpoints, such as mean HbA1c reduction or pain scores, when comparing the drug to a non-active control. These observed differences are the basis for evaluating the medicine’s profile.

Q: Is Aphen used to treat anything other than its main indication?

While the primary official use is described as multi-action relief from pain and inflammation, clinical research studies have also investigated its potential effects in other areas. For example, some studies have focused on its association with outcomes in conditions like Type 2 Diabetes Mellitus.

Q: How does the action of Aphen differ from other medicines for the same condition?

Official documents describe Aphen as a combination product that utilizes a dual or triple mechanism of action. This distinguishes its physiological mode of effect, as it targets pain via both peripheral (e.g., COX-2 inhibition) and central nervous system pathways.

Q: Does Aphen have a risk of dependence or withdrawal symptoms?

Regulatory warnings and precautions sections explicitly state that Aphen does not have a known risk of dependence, abuse, or typical withdrawal symptoms associated with controlled substances.

Q: How long does Aphen stay in your system after stopping it?

Regulatory pharmacokinetic data provides the elimination half-life of the active ingredients (the time required for the concentration to reduce by half). This time frame serves as the factual basis for estimating total drug clearance from the system.

Q: Is Aphen considered safe for long-term use?

Official guidelines for over-the-counter use restrict the duration to a short-term period, typically no more than 10 days for adults or 5 days for children. Long-term use is typically addressed only under the specific supervision of a health professional.

Q: What is the purpose of the different strengths Aphen is available in?

Different strengths are established by regulatory bodies to support the ability of healthcare providers to prescribe a range of appropriate dosages. This system respects the mandatory maximum daily limits set by regulatory guidelines.

Q: Can Aphen be crushed or split if the pills are too large?

Official administration and handling instructions specify whether tablets are scored and how they should be handled to ensure the integrity of the formulation and proper drug release mechanism.

Q: Can Aphen affect my ability to drive or operate machinery?

Official regulatory documents include a specific warning stating that the medicine may cause effects, such as dizziness or central nervous system effects, that could potentially impair the ability to drive or safely operate complex machinery.

Q: Are there known interactions between Aphen and cold or flu medicines?

Official warnings exist against co-administering Aphen with other Acetaminophen-containing products and certain Hepatic Microsomal Enzyme Inducers. These classes frequently include ingredients found in over-the-counter cold and flu preparations.

Q: Do many people report [common non-serious side effect] when taking Aphen?

Regulatory safety data categorizes certain side effects, such as nausea and dizziness, as Very Common (ge 1/10). Other effects like insomnia and headache are categorized as Common (ge 1/100), providing a descriptive sense of frequency.

Q: What's the general patient experience like when first starting Aphen?

Official safety information notes that gastrointestinal discomfort may be more frequent during the initial 4–6 weeks of therapy. This information helps establish general expectations for the initial adjustment period.

Q: Is it normal to feel a bit tired when starting Aphen?

Regulatory documents list side effects related to the central nervous system, such as Dizziness (Very Common) and Insomnia (Common). These effects may be associated with feelings of tiredness or fatigue.

Q: What are the most common reasons patients stop taking Aphen?

Regulatory data details the frequency of adverse reactions, where Very Common side effects like nausea and dizziness are typically reported. These common side effects are often the factors that influence patient tolerability in clinical settings.

Q: Does Aphen cause weight gain or loss?

Clinical trials investigated the compound's association with changes in body weight in specific populations. The research reports describe a range of observed effects from baseline rather than a definitive claim of gain or loss.

Q: Can Aphen cause changes in mood or personality?

Official safety profiles document adverse reactions related to the nervous system, such as insomnia and headache. However, regulatory documents do not explicitly list general mood or personality changes.

Q: Do official documents mention hair loss as a possible side effect of Aphen?

Regulatory safety data does not list alopecia (hair loss) within the documented adverse reactions organized by frequency or system-organ class.

Q: Is it typical for Aphen to cause vivid dreams?

Regulatory safety data does not specifically list vivid dreams as a reported adverse reaction within the documented frequency categories. Insomnia and headache are the more common nervous system effects listed.

Q: Do studies suggest Aphen is effective for all patients?

Research reports describe the average efficacy observed in specific, predefined trial populations. Regulatory documents do not contain guarantees of universal effectiveness for all individuals.

Q: Can I take Aphen if I have a history of [common chronic condition, e.g., high blood pressure]?

Regulatory labeling identifies specific, severe pre-existing conditions (e.g., severe heart, hepatic, or renal failure) as contraindications that strictly prohibit its use. The use of the medicine requires a comprehensive review of health history against all listed contraindications and precautions.

Q: Can women who are planning pregnancy use Aphen?

Aphen is officially listed as contraindicated during the last trimester of pregnancy, and its use is not generally recommended at other times. This position is based on documented fetal risk concerns described in regulatory sources.

Q: Is Aphen safe to use during breastfeeding?

Official guidance reflects the drug's presence in breast milk and the potential effects on a nursing infant, and the labeling describes the need for caution or contraindication due to limited safety data.

How should Aphen be stored and disposed of?

Storage and Disposal of Aphen

Storage and disposal must strictly adhere to officially documented regulatory requirements to maintain product stability and ensure safety.


Official Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at controlled room temperature, not exceeding 30°C.
Protection Keep in the original package, protected from light and moisture.
Handling Do not refrigerate or freeze. The container should be kept tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Aphen safely, preferably through an authorized medicine take-back program or pharmacy collection point. Do not dispose of the medication via household waste or wastewater unless specific at-home procedures are officially outlined by regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aphen found in:

A-Z Index: